Creating a new type of chemotherapy for peritoneal cancers
Official title: MANUFACTURING OF TPM SUITABLE FOR HUMAN USE
Funded at Leidos Biomedical Research, INC. · NIH-10941243 · Data updated 2026-11-12
This study is testing a new way to deliver chemotherapy directly into the abdomen for people with peritoneal cancers, hoping to make the treatment more effective by getting the medicine closer to the tumors.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Leidos Biomedical Research, INC. NIH-funded |
| Lab location | 1 site (Frederick, United States) |
| Project start | September 15, 2023 |
| Project end | September 14, 2028 |
| Funding year | 2023 |
| Award (this year) | $1,546,809 |
| NIH project number | 75N91019D00024-0-759102300022-1 |
| Project ID | NIH-10941243 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with peritoneal cancers who may benefit from intraperitoneal chemotherapy.
✕Less likely to help
Patients with cancers not located in the peritoneal cavity or those who are not candidates for chemotherapy may not receive benefit from this research.
What this research studies
This research focuses on developing a new formulation of chemotherapy that can be administered directly into the abdominal cavity for patients with peritoneal cancers. Traditional intravenous chemotherapy often fails to effectively reach solid tumors due to poor blood flow and high pressure within the tumors. By manufacturing a suitable formulation for intraperitoneal use, the research aims to enhance drug delivery and improve treatment outcomes. The study addresses the limitations of existing therapies, such as inadequate tumor penetration and associated complications.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates for patients with peritoneal cancers by providing more effective chemotherapy options.
How similar studies have gone: Previous studies have shown promising results with intraperitoneal chemotherapy, indicating that this approach has potential for success.
Where this research is happening
-
Leidos Biomedical Research, INC.
Frederick, United States Active
Researchers
- Principal investigator: Moore, Max — Leidos Biomedical Research, INC.
- Study coordinator: Moore, Max
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.